Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal: A quasi abstinence approach

Kusnandar Anggadiredja, Taku Yamaguchi, Hiroyuki Tanaka, Yukihiro Shoyama, Shigenori Watanabe, Tsuneyuki Yamamoto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Cannabinoid withdrawal has been indicated in both human and animal subjects. One of pathways proposed to facilitate cannabinoid action is the arachidonic acid cascade. Previously, we have shown that prostaglandin attenuated the expression of withdrawal signs in tetrahydrocannabinol-dependent mice. It follows that the cascade might participate in the expression of cannabinoid withdrawal. We utilized a quasi abstinence approach (the induction of a state of cannabinoid withdrawal without giving any cannabinoid substances in a naïve animal) to describe the relationship between the change in prostaglandin level, an end product of the arachidonic acid cascade, and the expression of cannabinoid withdrawal. Administration of 10 mg/kg diclofenac, a prostaglandin synthesis inhibitor, i.p. 30 min before SR 141716A induced cannabinoid withdrawal signs in naïve mice, which were comparable to the true abstinence in cannabinoid-tolerant mice. In turn, 10 mg/kg Δ8-THC i.p., given 15 min prior to SR 141716A, blocked the expression of these signs. These results suggested that the decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal.

Original languageEnglish
Pages (from-to)201-205
Number of pages5
JournalBrain Research
Volume1066
Issue number1-2
DOIs
Publication statusPublished - Dec 20 2005

Fingerprint

Cannabinoids
Prostaglandins
rimonabant
Dronabinol
Arachidonic Acid
Prostaglandin Antagonists
Diclofenac

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology

Cite this

Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal : A quasi abstinence approach. / Anggadiredja, Kusnandar; Yamaguchi, Taku; Tanaka, Hiroyuki; Shoyama, Yukihiro; Watanabe, Shigenori; Yamamoto, Tsuneyuki.

In: Brain Research, Vol. 1066, No. 1-2, 20.12.2005, p. 201-205.

Research output: Contribution to journalArticle

Anggadiredja, K, Yamaguchi, T, Tanaka, H, Shoyama, Y, Watanabe, S & Yamamoto, T 2005, 'Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal: A quasi abstinence approach', Brain Research, vol. 1066, no. 1-2, pp. 201-205. https://doi.org/10.1016/j.brainres.2005.10.065
Anggadiredja, Kusnandar ; Yamaguchi, Taku ; Tanaka, Hiroyuki ; Shoyama, Yukihiro ; Watanabe, Shigenori ; Yamamoto, Tsuneyuki. / Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal : A quasi abstinence approach. In: Brain Research. 2005 ; Vol. 1066, No. 1-2. pp. 201-205.
@article{7d57d809893e4a41b0834e9752da2442,
title = "Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal: A quasi abstinence approach",
abstract = "Cannabinoid withdrawal has been indicated in both human and animal subjects. One of pathways proposed to facilitate cannabinoid action is the arachidonic acid cascade. Previously, we have shown that prostaglandin attenuated the expression of withdrawal signs in tetrahydrocannabinol-dependent mice. It follows that the cascade might participate in the expression of cannabinoid withdrawal. We utilized a quasi abstinence approach (the induction of a state of cannabinoid withdrawal without giving any cannabinoid substances in a na{\"i}ve animal) to describe the relationship between the change in prostaglandin level, an end product of the arachidonic acid cascade, and the expression of cannabinoid withdrawal. Administration of 10 mg/kg diclofenac, a prostaglandin synthesis inhibitor, i.p. 30 min before SR 141716A induced cannabinoid withdrawal signs in na{\"i}ve mice, which were comparable to the true abstinence in cannabinoid-tolerant mice. In turn, 10 mg/kg Δ8-THC i.p., given 15 min prior to SR 141716A, blocked the expression of these signs. These results suggested that the decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal.",
author = "Kusnandar Anggadiredja and Taku Yamaguchi and Hiroyuki Tanaka and Yukihiro Shoyama and Shigenori Watanabe and Tsuneyuki Yamamoto",
year = "2005",
month = "12",
day = "20",
doi = "10.1016/j.brainres.2005.10.065",
language = "English",
volume = "1066",
pages = "201--205",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal

T2 - A quasi abstinence approach

AU - Anggadiredja, Kusnandar

AU - Yamaguchi, Taku

AU - Tanaka, Hiroyuki

AU - Shoyama, Yukihiro

AU - Watanabe, Shigenori

AU - Yamamoto, Tsuneyuki

PY - 2005/12/20

Y1 - 2005/12/20

N2 - Cannabinoid withdrawal has been indicated in both human and animal subjects. One of pathways proposed to facilitate cannabinoid action is the arachidonic acid cascade. Previously, we have shown that prostaglandin attenuated the expression of withdrawal signs in tetrahydrocannabinol-dependent mice. It follows that the cascade might participate in the expression of cannabinoid withdrawal. We utilized a quasi abstinence approach (the induction of a state of cannabinoid withdrawal without giving any cannabinoid substances in a naïve animal) to describe the relationship between the change in prostaglandin level, an end product of the arachidonic acid cascade, and the expression of cannabinoid withdrawal. Administration of 10 mg/kg diclofenac, a prostaglandin synthesis inhibitor, i.p. 30 min before SR 141716A induced cannabinoid withdrawal signs in naïve mice, which were comparable to the true abstinence in cannabinoid-tolerant mice. In turn, 10 mg/kg Δ8-THC i.p., given 15 min prior to SR 141716A, blocked the expression of these signs. These results suggested that the decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal.

AB - Cannabinoid withdrawal has been indicated in both human and animal subjects. One of pathways proposed to facilitate cannabinoid action is the arachidonic acid cascade. Previously, we have shown that prostaglandin attenuated the expression of withdrawal signs in tetrahydrocannabinol-dependent mice. It follows that the cascade might participate in the expression of cannabinoid withdrawal. We utilized a quasi abstinence approach (the induction of a state of cannabinoid withdrawal without giving any cannabinoid substances in a naïve animal) to describe the relationship between the change in prostaglandin level, an end product of the arachidonic acid cascade, and the expression of cannabinoid withdrawal. Administration of 10 mg/kg diclofenac, a prostaglandin synthesis inhibitor, i.p. 30 min before SR 141716A induced cannabinoid withdrawal signs in naïve mice, which were comparable to the true abstinence in cannabinoid-tolerant mice. In turn, 10 mg/kg Δ8-THC i.p., given 15 min prior to SR 141716A, blocked the expression of these signs. These results suggested that the decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal.

UR - http://www.scopus.com/inward/record.url?scp=29044439110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29044439110&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2005.10.065

DO - 10.1016/j.brainres.2005.10.065

M3 - Article

C2 - 16336946

AN - SCOPUS:29044439110

VL - 1066

SP - 201

EP - 205

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -